bioRASI to Exhibit at the 2012 GPhA Annual Meeting in Orlando, FL
The Leading ANDA and 505(b)(2) CRO to Showcase Ophthalmic Clinical Program Optimization Techniques
(firmenpresse) - AVENTURA, FL -- (Marketwire) -- 02/21/12 -- bioRASI, a full service, global Contract Research Organization (CRO), announced today that they will participate at the 2012 GPhA Annual Meeting in Orlando, Florida on February 22 - 24th. bioRASI will be exhibiting at booth #6 and will showcase its strategies and solutions for optimizing ophthalmic drugs development programs.
bioRASI will be introducing a new ophthalmology issue in their White Papers Series highlighting clinical endpoint ANDA Program Optimization techniques for the generics and specialty pharmaceutical industry.
"The share of ophthalmic drugs within most generic pipelines has been growing rapidly. bioRASI has emerged as the leader in conducting ophthalmology clinical studies," said Dr. Boris Reznik, Chairman of bioRASI. "Our Ophthalmology Program Management team consists of several MDs and MDs/PhDs in ophthalmology. This background coupled with many years of ophthalmic clinical trials experience makes bioRASI's ability to optimize these programs second to none."
bioRASI publishes the white papers several times a year, addressing and analyzing different aspects of optimization, and making them available on their website, at marketing and technical conferences and through other established electronic publishing services.
.
Bill Doyle
(786) 388-0700
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.02.2012 - 15:36 Uhr
Sprache: Deutsch
News-ID 1085265
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
AVENTURA, FL
Phone:
Kategorie:
Trials
Anmerkungen:
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"bioRASI to Exhibit at the 2012 GPhA Annual Meeting in Orlando, FL
"
steht unter der journalistisch-redaktionellen Verantwortung von
bioRASI (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
